Antiviral drug Remdesivir gains 3 patents in China

0 Comment(s)Print E-mail Xinhua, February 26, 2020
Adjust font size:
A staff member handles nucleic acid testing samples at a novel coronavirus detection lab in Wuhan, central China's Hubei Province, Feb. 22, 2020. [Photo/Xinhua]

The antiviral drug Remdesivir, which is under clinical trials for treating the novel coronavirus disease (COVID-19), has been granted three patents in China, according to an official Tuesday.

The American pharmaceutical company Gilead Sciences has applied for eight patents on the drug, three of which have been approved and the other five are being reviewed, said He Zhimin, deputy director of the National Intellectual Property Administration at a press conference.

The eight patents cover the core and similar structures of the compounds, manufacturing methods and applications, He said.

The clinical trial of the drug is currently in progress and the results are expected to be released on April 27, He added.

Follow on Twitter and Facebook to join the conversation.
ChinaNews App Download
Print E-mail Bookmark and Share

Go to Forum >>0 Comment(s)

No comments.

Add your comments...

  • User Name Required
  • Your Comment
  • Enter the words you see:    
    Racist, abusive and off-topic comments may be removed by the moderator.
Send your storiesGet more from